Neurology conference presents positive news for Elan

There was good news for embattled Athlone-based pharmaceutical company Elan overnight after data presented at a neurology conference showed treatment with under-fire multiple sclerosis (MS) drug Tysabri led to a significant reduction in progression of the disease.

Two-year data from the Affirm Phase III monotherapy trial presented at the conference for the first time, showed that treatment with Tysabri led to a 42% reduction in the rate of clinical relapses and brain lesions in patients with relapsing forms of MS.